Stanford University on varicella and zoster in patients immunosuppressed by disease and treatment.
Also during the 1970s the first results emerged of the studies of osteogenic sarcoma in Sweden, which seemed to show that recurrence of the disease after primary treatment was less in patients given regular intramuscular interferon. These trials could be criticized and were, but they emphasized the importance of experimental work on the wide-ranging effects of interferon. In particular Gresser, in Paris, showed how tumours of mice, not caused by viruses, might be inhibited by a direct reduction of the rate of growth of the cells, or more likely by effects on the host defence mechanism. There was widespread work showing that interferon could modulate the immune system, particularly by an effect on T lymphocytes, but also stimulated other systems, such as natural killer (NK) cells. In fact, it became clear that interferon is one of the lymphokines responsible for regulation of cellular responses.
Reference has not been made to the long-continued studies on the biochemistry of interferon, which has recently shown in some detail how the synthesis of viral protein is impaired without general danger to the cell. It is interesting, though, that the interest in dsRNA and the way interferon synthesis might be regulated led to the development of large scale production of human fibroblast interferon (IFNfJ). The clinical potential of this is only now being evaluated.
The first efforts to purify interferon began immediately after 1957 and were carried on in many laboratories using chicken, mouse and human interferon. In the last few years, almost exactly twenty years later, success has been achieved, and with modern technology the very small amounts available have been used to obtain preliminary evidence on the amino acid sequence of the molecule. DNA for interferon has now been cloned into bacteria and sequenced (Mantei et al. 1980 , Taniguchi et al. 1980 and the amino acid sequences deduced from that are now being checked. Furthermore, human interferon has now been produced in bacteria and we can expect useful amounts for clinical study to become available in the next few years. Once this technique is developed we shall not be constrained by lack of material for either research or clinical use.
Thus there has been an explosion of knowledge about the chemical and molecular basis of the interferons, but there is still much more to be learned in this field and in the biological significance and clinical application of these substances. An exciting period lies ahead.
